Ipsen Expands Pipeline with Innovative Antibody-Drug Conjugate

Paris-based Ipsen has secured global rights, excluding Greater China, for Simcere Zaiming's SIM0613, an antibody-drug conjugate (ADC). The partnership aims to enhance cancer treatment through superior tumor penetration. This marks a significant step for Ipsen in oncology innovation. SIM0613 will begin Phase I clinical trials in the second half of 2026.

Designed to target the LRRC15 protein, highly expressed in certain tumors, SIM0613 is expected to demonstrate robust anti-tumor activity. Ipsen plans to manage development and commercialization outside Greater China. Simcere Zaiming stands to gain up to $1.06 billion through various milestone payments subject to successful development.

This collaboration demonstrates Ipsen’s commitment to pioneering cancer therapies. Over 20 programs have joined Ipsen’s growing development portfolio since 2020.